[Are we prepared to diagnose and managed malignant hyperthermia?].
OBJECTIVE
Malignant Hyperthermia (MH) is an uncommon but potentially lethal disease associated to halogenate agents and/or succinylcholine exposure. Resulting mortality and morbidity may be decreased by early diagnosis and specific treatment, including sodium dantrolene. Brazil has approximately 160 million inhabitants assisted by more than 6000 anesthesiologists. In the last decade, special attention was given to this disease, resulting in better informed anesthesiologists and more prepared hospitals to treat malignant hyperthermia (MH). This study aimed at measuring the level of information of Brazilian anesthesiologists regarding MH, in order to develop new approaches to control this disease.


METHODS
A questionnaire with 20 questions on malignant hyperthermia diagnosis, prevention and treatment was mailed to the 6,164 members of the Brazilian Society of Anesthesiology.


RESULTS
Questionnaires were returned by 646 anesthesiologists (10.4%). More than 90% of correct answers about clinical diagnosis and treatment were obtained. On the other hand, nearly 50% of anesthesiologists gave incorrect answers about muscle biopsy indication and clinical pharmacology of dantrolene.


CONCLUSIONS
Results have indicated adequate knowledge about this topic, but has shown that some relevant issues need additional attention. The number of answers was significant to evaluate MH understanding of Brazilian anesthesiologists, but has also shown poor motivation. From these results it is possible to conclude that it is essential to intensify continuing education programs, contemplating all issues of this major anesthetic subject.
Simões
Claudia Marquez
CM
CET, SBA, Faculdade de Medicina, USP.
Koishi
Giovanna Negrisoli
GN
Rozatti
Marcelo
M
Amaral
José Luiz Gomes do
JL